
Nephrologist MD @NephroCare| Member SoMe Team @erakidney | Main interests: Dialysis, Conservative Care of ESRD; CKD โpandemicโ; AI impact on healthcare delivery
Faro, Portugal
Joined July 2022
- Tweets603
- Following603
- Followers339
- Likes484
Pinned Tweet
โจ Such a privilege to have chaired a FO #ERA26 where @VladoPerkovic presented the unpublished preliminary results from the VISIONARY Phase 3 trial, showing a slower eGFR decline in IgAN patients treated with sibeprenlimab. The therapeutic options for IgAN continues to expand๐
12
547
Elsa Morgado ๐ต๐น retweeted
Charles is already making me uncomfortable just based off its satellite presentation (bottom left).
IPMA has issued red warnings for wind gusts as high as 140 km/h in continental Portugal.
I will be posting frequent updates on the evolution of Charles as it makes its approach to Madeira and Portugal, if you can share these updates then feel free to do so.
๐ First autumn weekend task: organising my novels! ๐ A quick count: 546 titles by 346 authors. ๐ต๐น Portugal: 156 | Rest of Europe: 197 | North America: 131 | South America: 28 | Asia: 22 | Africa: 3. Plus 9 from Oceania/other. ๐
#BookLovers #BookTwitter #Novels #BookCollection
47
๐One step closer to immortality? ๐งฌโพ๏ธ Semaglutide started late in life slows ageing AND extends lifespan. This is a breakthrough. ๐ฅ
๐๏ธnature.com/articles/s41586-0โฆ
170
Congratulations ๐ฅณ ๐ to the beautiful country and kind people of Cabo Verde๐จ๐ป! Well done!
I know everyone in Portugal๐ต๐น is cheering for them too! I definitely am!
๐ฅณ ยกLa emociรณn de saber que acabas de hacer historia!
๐จ๐ป El momento en el que Cabo Verde se enterรณ que era la 2ยช clasificada del Grupo H.
133
Elsa Morgado ๐ต๐น retweeted
๐ Weโre delighted to share the latest Impact Factors and CiteScores for our leading nephrology journals Nephrology Dialysis Transplantation (NDT) and Clinical Kidney Journal (CKJ).
๐ Our heartfelt gratitude goes to the exceptional contributions of our authors, reviewers, readers, and editorial board.
Check out the new hosts @HDiniz_ e @dianarodespi !
๐ง Catch a sneak peek of the next three episodes, dropping on June 18, 2026, and meet one of the new voices of the podcast, Hugo Diniz! โฃโฃ
๐ Available on Apple Podcasts, Spotify, YouTube, Amazon Music, and more! โฃโฃ
Listen now ๐ bit.ly/4koNiIv
๐ We often focus on nutrients, calories and weight. But perhaps we should also be paying more attention to food processing itself.
An eye-opening session at #ERA26 on how ultra-processed foods may impact kidney health through pathways extending far beyond obesity. ๐ฉบ๐ฆ
Replying to @ERAkidney
๐งต 2/10 The dangers of Ultraprocessed Foods in CKD: Exploring Possible Solutions. #ERA26
๐ฌ Carla Maria Avesani
๐Can UPFs contribute to obesity, CKD progression, and poorer metabolic health? The evidence presented suggests the answer may be yes.
1
1
171
๐งฉ The obesityโCKD connection is far more complex than BMI alone!
From metabolic pathways to kidney protection strategies, this session highlighted why every step counts. ๐ฉบโ๏ธ #ERA26
Replying to @ERAkidney
142
A negative trial, but not a negative message. ๐ก
GOOD-IDES-02 at #ERA26 reminds us that in anti-GBM disease, rapid antibody removal with imlifidase is biologically compelling ๐งฌ โ even if translating that into kidney outcomes remains challenging. ๐ฉบ
#ChallengeYourThinking
1/6 ๐งต #ERA26 - High impact clinical trials in Nephrology. #ChallengeYourThinking
๐ช Chairs: Mario Gennaro Cozzolino @MarioCozzolin19, Kaitlin Mayne
GOOD-IDES-02: a randomized controlled phase 3 trial testing imlifidase treatment in anti-GBM disease โ outcomes and post hoc analysis
๐Anti-GBM disease remains one of the most devastating nephrological emergencies.
๐Could rapid antibody depletion with imlifidase improve outcomes beyond current standard therapy?
๐ฌ Mรฅrten Segelmark
Another fascinating #ERA26 layer to the SGLT2i story
Beyond cardiorenal protection, this meta-analysis suggests a class effect on Hb/Hct๐ฉธ โ likely reflecting coordinated effects on erythropoiesis and iron homeostasis, not just hemoconcentration.
#ChallengeYourThinking
1/6 ๐งต #ERA26 - High impact clinical trials in Nephrology. #ChallengeYourThinking
๐ช: Mario Gennaro Cozzolino @MarioCozzolin19; Kaitlin Mayne
Effects of SGLT2 inhibitors on erythropoiesis and iron homeostasis: a systematic review and meta-analysis exploring how these agents may raise Hb/Hct beyond simple hemoconcentration.
๐ฌ Speaker: Michele F. Eisenga
2
184
A very practical #ERA26 message from CONCORDIA: HDx with Theranova showed non-inferior all-cause mortality compared with HDF in a real-world analysis.
Same survival, middle-molecule clearance, and standard HD infrastructure โ definitely worth following.
#ChallengeYourThinking
1/6 ๐งต #ERA26 - High impact clinical trials in Nephrology. #ChallengeYourThinking
๐ช Chairs: Mario Gennaro Cozzolino @MarioCozzolin19, Kaitlin Mayne @KaitlinMayne
The CONCORDIA Study: All-Cause Mortality with HDx with Theranova Compared with Hemodiafiltration Using DOPPS as an External Real-World Comparator. Can expanded HD match HDF?
๐ฌ Speaker: Roberto Pecoits-Filho @pecoitsfilho
Elsa Morgado ๐ต๐น retweeted
1/6 ๐งต #ERA26 - High impact clinical trials in Nephrology. #ChallengeYourThinking
๐ช Chairs: Mario Gennaro Cozzolino @MarioCozzolin19, Kaitlin Mayne @KaitlinMayne
The CONCORDIA Study: All-Cause Mortality with HDx with Theranova Compared with Hemodiafiltration Using DOPPS as an External Real-World Comparator. Can expanded HD match HDF?
๐ฌ Speaker: Roberto Pecoits-Filho @pecoitsfilho
Exciting complement-targeted data in IgA nephropathy at #ERA26 ๐
Ravulizumab showed a rapid and sustained proteinuria โฌ๏ธ in the phase 3 I CAN interim analysis โ a trial to watch closely in the evolving IgAN landscape.
#ChallengeYourThinking
1/7 ๐งต #ERA26 - High impact clinical trials in Nephrology. #ChallengeYourThinking
๐ช: Mario Gennaro Cozzolino @MarioCozzolin19; Kaitlin Mayne
Ravulizumab in IgA nephropathy: a prespecified interim analysis of the phase 3 I CAN trial. Promising complement-targeted data in IgAN.
๐ฌ: Jonathan Barratt @IgAN_JBarratt
What a vibe, right?
Finerenone in CKD!!
It's raining publications - NEJM, JAMA, Lancet, NDT
Live from #ERA26
5
300
Harnessing the powerโก of dual (and perhaps triple) incretin therapies may be one of the most exciting ๐คฉfrontiers in CKD. #ERA26
๐งต1/8
Obesity in CKD - part I/III
This #ERA26 symposium challenged us to think beyond weight loss &BMI โ๏ธ, and also to reflect on the impact of the increasing ๐ consumption of Ultraprocessed Foods (UPF)๐๐๐ฅค.
#ChallengeYourThinking #CKD #Obesity
๐ช Ziad Massy @MassyZiad
๐ช Inga Arune Bumblyte
2
156
๐คฉSuch an exciting moment at #ERA26 to witness, in real time, another pillar being added to the pantheon of CKD therapies as @KatherineTuttle8 wraps it up with the FIND-CKD and INFINITY trials. ๐๐ฉบ
3
119
๐๐LBCT II at #ERA26 with the presentation of the results of the FIND-CKD study! Uau. In a CKD population with a mean eGFR ~40ml/min fiberenone โฌ๏ธโฌ๏ธthe kidney +๐ซ composite end point by 23%!
Simultaneous publication in NEJM!!!
๐คฉNothing captures the excitement of #ERA26 quite like a study being presented and published at the same time. Science moving at full speed. ๐๐ฌ
1st simultaneous publication of the day #ERA26 @HyperAHA
๐Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure
โ๏ธBy @AgarwalRajivMD and co
ahajournals.org/doi/10.1161/โฆ
1
4
613
Which one is your favourite โค๏ธ sticker from #ERA26? Which one would you print on a t-shirt! Iโm divided between โKidney Rocksโ and โFiltering Out Bad Vibes! ๐
8
107























